Recent briefings covering the period to 17 June 2026 contained no material Eli Lilly-specific disclosures. Macro commentary centred on geopolitical escalation in the Middle East, including a confirmed Israeli strike on Iran's Mahshahr petrochemical complex on 8 June 2026 that drove Brent crude to $94 per barrel during the European session — the first confirmed energy-sector attack since an April ceasefire, per OilPrice.com [Brief - 2026-06-09]. Separately, Iranian drone and missile strikes on Kuwait International Airport and Ali Al Salem Air Base were reported on 3 June 2026, prompting suspension of Kuwaiti air traffic [Brief - 2026-06-03]. Neither event generated direct LLY-specific disclosures in the briefing record.
Eli Lilly's trailing-twelve-month financials as of 31 March 2026 reflected revenue of $72.25 billion, representing year-over-year growth of 55.5%. Net income over the same period was $25.28 billion, producing a net margin of 34.99%. Earnings per share grew 169.93% year-over-year. The company held $5.28 billion in cash against total debt of $43.37 billion. The reported price-to-earnings ratio stood at 39.88 [SEC 10-Q - LLY - 2026-03-31].
Insider activity over the past 30 days comprised nine transactions with a net selling direction, totalling approximately $2.88 million in net disposition value [SEC Form 4 - LLY - 2026-06]. Institutional ownership saw notable divergence in the most recent 13F filing period. Citadel reduced its LLY position by 29%, and Millennium Management reduced its position by 6.5%. Conversely, AQR Capital added 69% to its existing position, and ARK Invest opened a new position in the company [SEC 13F - Citadel - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - ARK Invest - Q1 2026].
The broader macro environment as of the report date showed the 10-year US Treasury yield at 4.47% and the 2-year yield at 4.07%, producing a normal yield curve spread of approximately 40 basis points [FRED DGS10] [FRED DGS2]. This report was triggered by material institutional position changes identified in the most recent 13F filing disclosures.